Related Experiment Video
Updated: Jan 10, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML
Abstract:
Nucleophosmin-1 ( NPM1 ) mutations define a major molecular subtype of acute myeloid leukemia (AML) and is generally associated with favorable prognosis. However, the impact of myelodysplasia-associated mutations (MDSm+) on patient outcomes within this subgroup remains uncertain. We retrospectively analyzed 271 NPM1 -mutated AML patients from three independent cohorts (SWOG, Fred Hutch, and Beat AML) to assess the prognostic significance of MDSm+ and its interaction with age. MDSm+ occurred in 17% of cases, most commonly involving SRSF2 and SF3B1 . Although MDSm+ was associated with inferior overall survival compared to MDSm-in ELN2022 favorable-risk patients (HR 2.0, p =0.008), this effect was largely driven by worse outcomes in older patients ( ≥ 65 years) as older ELN22 favorable-risk patients had poor OS regardless of presence of MDSm+ compared to younger patients. After stratification of patients by age, there was not a significant difference between MDSm+ and MDSm-in either younger patients (HR 0.99, p=0.98) or older patients (HR 1.42, p =0.33). These findings indicate that MDSm+ in NPM1 + AML is not independently associated with adverse risk after adjusting for age and highlight the need for age-adjusted AML risk models.
Insights
Myelodysplasia-associated mutations (MDSm+) do not independently worsen outcomes in Nucleophosmin-1 (NPM1)-mutated acute myeloid leukemia (AML). Age is a critical factor, suggesting a need for age-adjusted risk models in AML patient stratification.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Nucleophosmin-1 (NPM1) mutations are a key molecular subtype of acute myeloid leukemia (AML), typically linked to a favorable prognosis.
- The prognostic impact of myelodysplasia-associated mutations (MDSm+) within the NPM1-mutated AML subgroup is not well-defined.
Purpose of the Study:
- To investigate the prognostic significance of MDSm+ in NPM1-mutated AML.
- To examine the interaction between MDSm+ and patient age on overall survival.
Main Methods:
- Retrospective analysis of 271 NPM1-mutated AML patients from three independent cohorts.
- Assessment of MDSm+ prevalence and specific mutation involvement (e.g., SRSF2, SF3B1).
- Survival analysis stratified by age and MDSm+ status.
Main Results:
- MDSm+ were identified in 17% of NPM1-mutated AML cases.
- MDSm+ showed an association with inferior overall survival in older patients (≥65 years).
- After age stratification, MDSm+ did not significantly impact survival in either younger or older patient groups.
Conclusions:
- MDSm+ is not an independent adverse prognostic factor in NPM1-mutated AML when age is considered.
- Current risk stratification models for AML may need to incorporate age-specific adjustments.
- Further research into age-adjusted risk models is warranted for NPM1-mutated AML.
Related Concept Videos
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:36Mismatch Repair
02:23Abnormal Proliferation